Skip to main content
Clinical Trials/CTRI/2022/07/043782
CTRI/2022/07/043782
Not yet recruiting
未知

To evaluate Ophthalmological safety of test product involving subjects of normal eye conditions on healthy female subjects.

ONESTO LABS PVT LTD0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ONESTO LABS PVT LTD
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
ONESTO LABS PVT LTD

Eligibility Criteria

Inclusion Criteria

  • 1\.Indian Female subjects
  • 2\.Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
  • 3\.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scarâ?¦.)
  • 4\.Having normal eye conditions
  • 5\.Having habit of using under eye cream

Exclusion Criteria

  • 6\.Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
  • 7\.Having refused to give his/her assent by not signing the consent form
  • 8\.Taking part in another study liable to interfere with this study
  • 9\.Being insulin\-dependent diabetic or non insulin\-dependent diabetic with a recent therapy (less than 6 months)
  • 10\.Having a progressive asthma (either under treatment or last fit in the last 2 years)
  • 11\.Being epileptic.
  • 12\.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
  • 13\.Having cutaneous hypersensitivity
  • 14\.Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • 15\.Following a chronic medicinal treatment comprising any of the following products: aspirin based products, anti\-inflammatories, anti\-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)

Outcomes

Primary Outcomes

Not specified

Similar Trials